Latest News
Latest News
Noninvasive NASH test could help monitor hepatotoxicity in patients on methotrexate
A noninvasive test for nonalcoholic steatohepatitis (NASH) and hepatic fibrosis can help monitor for hepatic fibrosis and could reduce the number...
From the Journals
Despite global decline, rheumatic heart disease persists in poorest regions
From 1990 to 2015, the percentage of deaths worldwide due to rheumatic heart disease rose in endemic regions of Oceania, South Asia, and central...
From the Journals
Axial SpA features don’t guarantee its diagnosis in chronic back pain
Even when patients with chronic back pain have four or more features of axial spondyloarthritis, a diagnosis of axial spondyloarthritis is not...
From the Journals
Musculoskeletal ultrasound training now offered in nearly all U.S. rheumatology fellowships
Rheumatology fellowship programs offering musculoskeletal ultrasound training grew from 60% in a 2013 survey to 94% in 2017.
From the Journals
Oral contraceptive use linked to lower rheumatoid arthritis risk
The decrease in risk was seen only in women with ACPA-positive RA.
Conference Coverage
How to make the move away from opioids for chronic noncancer pain
How do physicians treat patients with chronic pain and guard against addiction?
From the Journals
Study shows more changes, less stopping of PsA systemic drugs
Between 2004 and 2015, about 43% of PsA patients were treated with a biologic agent, results from a large study of national claims data showed.
Feature
Physicians shift on support of single-payer system
Opinions “appear to have evolved” since a 2008 survey, when the majority of physicians opposed it.
Conference Coverage
Helpful schedules ease task of tapering opioids
ESTES PARK, COLO. – Patients generally tolerate gradual weaning to 30%-50% of original dose.
Feature
CBO: End of ACA subsidies would mean short-term exit of insurers
The availability of plans is expected to rebound.
From the Journals
Analysis: Gabapentinoids aren’t the answer to back pain
There’s little evidence that pregabalin and gabapentin are effective for chronic lower back pain, but they do carry risks of side effects.